NY-ESO Phase I Study for Prostate Cancer

  • STATUS
    Recruiting
  • participants needed
    38
  • sponsor
    Baylor College of Medicine
Updated on 7 November 2020

Summary

Prostate cancer is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007. About 27,050 men will die of this disease. Prostate cancer is the second leading cause of cancer death in men. Lung cancer is the first. While 1 man in 6 will get prostate cancer during his lifetime, only 1 man in 34 will die of this disease. The death rate for prostate cancer is going down, and the disease is being found earlier as well. There is a great need for new treatment options for prostate cancer that can be given safely. One alternative to widely used conventional cancer treatments is to utilize the ability of the patient's immune system to target and kill tumor cells. A vaccine is a compound designed to strengthen the immune system (the cells and substances that protect the body from infection and foreign matter) to fight an illness such as infections or cancer. This vaccine is called NY-ESO-1 protein. NY-ESO protein (an antigen, which is a compound that is recognized by the immune system) is found in many cancers. Proteins such as NY-ESO-1 and LAGE-1 and their fragments are the targets the immune system needs to recognize cancer cells. If the immune system can recognize these antigens (foreign substances) it may be able to kill the cells that carry them. NY-ESO-1 can be found at different stages of cancers, and is likely to be expressed (shown) at some point in the lifecycle of these types of cancer (that are eligible for this study). Therefore this study tries to boost (strengthen) the immune system toward NY-ESO-1 protein regardless of whether it is found in the tumor or not.

Description

Nine subjects will participate in this Phase I study that is designed to evaluate the safety and biology of class I and class II NY-ESO-1/LAGE-1 vaccine with an intent to offer a therapeutic advantage. The treatment cycle is 6 subcutaneous injections administered every other week for 12 weeks of NY-ESO-1/LAGE-1 vaccine (weeks 1, 3, 5, 7, 9, 11 (±3 days)). The vaccinations will be given in the upper arm region, in a volume of 1 milliliter. The dose will be 1000 mcg of peptide (1 mg). Patients will be evaluated for clinical/immunological responses at weeks 5 and 11. The vaccine schedule is similar to that of many prior peptide vaccine studies, in which the schedule was based on earlier animal studies but empirically derived in human studies (32-34, 36-39). The first patients will be enrolled to receive subcutaneous vaccination with either class I or II NY-ESO-1/ LAGE-1 peptide (1000 mcg). Thus, the trial will test the toxicity of the vaccine with 3 patients in each of 2 vaccine groups, one receiving Class I (group I) and the other Class II peptide (group II). If no significant toxicity is observed after a treatment cycle of 12 weeks, then three patients will receive a combination of both peptides (group III).

Details
Condition Prostatic Neoplasms
Treatment NY-ESO-1 class I and class II peptide vaccine, LAGE-1 class I and class II peptide vaccine
Clinical Study IdentifierNCT00711334
SponsorBaylor College of Medicine
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note